Adherence with direct oral anticoagulants in patients with atrial fibrillation: Trends, risk factors, and outcomes

Abstract

This is an open access article under the terms of the Creat ive Commo ns Attri bution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Group-Based Trajectory Modeling to Identify Adherence Patterns for Direct Oral Anticoagulants in Medicare Beneficiaries with Atrial Fibrillation

“…Patients prescribed with antihyperlipidemic agents were less likely to be associated with lower adherence trajectory and is consistent with the prior body of evidence [26,33,34]. This may be plausible as patients who are adherent to other cardiovascular medications like statins could have better adherence to DOACs as well [33,34]. Finally, patients prescribed with twice daily Apixaban were more likely to fall into nonadherent trajectories as compared to the once daily rivaroxaban as it may be plausible due to the pill burden [35,36].…”

“…Bleeding complications among DOAC users may cause treatment discontinuation [31].Patients with comorbidities like hypertension, renal disease, and coronary artery disease were at higher risk of being associated with lower adherence trajectories [6,32]. Patients prescribed with antihyperlipidemic agents were less likely to be associated with lower adherence trajectory and is consistent with the prior body of evidence [26,33,34]. This may be plausible as patients who are adherent to other cardiovascular medications like statins could have better adherence to DOACs as well [33,34].…”